Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Peptide Therapeutics Market

U.S. Peptide Therapeutics Market Share

Report ID: GMI7400
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

U.S. Peptide Therapeutics Market Share

The key players in peptide therapeutics market are

Pfizer, Inc.
Amgen, Inc.
Eli Lilly and Company
Sanofi
AstraZeneca plc
AbbVie, and GlaxoSmithKline plc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S peptide therapeutics industry size was USD 17.8 billion in 2022 and is expected to register 7% CAGR from 2023-2032 due to the increasing prevalence of chronic disorders, rising healthcare expenditure, technological advancements, and the growing disposable incomes in the region.

U.S peptide therapeutics industry from the branded type segment is expected to record USD 22,830 million by 2032 owing to the higher number of prescriptions for branded drugs, and the perceived quality and efficacy of branded peptide therapeutics compared to generics.

U.S peptide therapeutics industry size from the in-house manufacturer segment held 64.4% share in 2022 owing to the increasing focusing on developing peptide therapeutics in-house due to the high costs and stringent outsourcing regulatory requirements.

Pfizer, Inc., Amgen, Inc., Eli Lilly and Company, Sanofi, AstraZeneca plc, AbbVie, and GlaxoSmithKline plc are some of the major peptide therapeutics companies in the U.S.